Welcome to tagrissoandme.co.uk*
This website is intended only for UK patients who have been prescribed TAGRISSO® (osimertinib)
*This website has been produced and funded by AstraZeneca UK.
This website is intended only for UK patients who have been prescribed TAGRISSO® (osimertinib)
*This website has been produced and funded by AstraZeneca UK.
Osimertinib is a targeted therapy for locally advanced and metastatic late-(stage 4) EGFR+ NSCLC2-4
Your NSCLC tested positive for a certain EGFR biomarker, which is why you and your doctor chose this drug.2
Osimertinib is a targeted therapy, which means it is a treatment that specifically attacks EGFR and blocks the growth and spread of lung cancer cells.2-4
Targeted therapies are not chemotherapy or immunotherapy.5
Talk to your healthcare professional about the importance of staying on track with your osimertinib treatment to help prevent your lung cancer from growing or spreading.3
Always keep communicating with your doctor and healthcare team so they know how you’re doing with your treatment. Be aware of any changes that you notice in your body and let them know if/ when you experience any side effects.3

References:
GB-73016 I DOP: January 2026